S&P 500   3,800.00
DOW   30,978.05
QQQ   315.86
S&P 500   3,800.00
DOW   30,978.05
QQQ   315.86
S&P 500   3,800.00
DOW   30,978.05
QQQ   315.86
S&P 500   3,800.00
DOW   30,978.05
QQQ   315.86
Log in
NYSE:PHR

Phreesia Stock Forecast, Price & News

$64.05
+1.09 (+1.73 %)
(As of 01/19/2021 12:59 PM ET)
Add
Compare
Today's Range
$62.97
Now: $64.05
$64.53
50-Day Range
$43.36
MA: $53.89
$63.73
52-Week Range
$16.01
Now: $64.05
$64.17
Volume11,996 shs
Average Volume379,464 shs
Market Capitalization$2.83 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.42
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company's Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments. It deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a Web-based dashboard for providers; PhreesiaPads, which are self-service intake tablets; and Arrivals Stations that are on-site kiosks. The company's Phreesia Platform also provides a registration solution to automate patient self-registration; patient activation solution that enables providers to communicate with their patients through surveys, announcements, messaging, and health campaigns; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, and cost estimation tools; clinical support solution that collects clinical intake and PRO data for approximately 25 specialties; appointments solution for online appointments, reminders, and referral tracking; and life sciences solution to deliver targeted and clinically relevant marketing content to patients. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and life sciences, pharmaceutical, medical device, and biotechnology companies. Phreesia, Inc. has a strategic alliance agreement with Allscripts Healthcare, LLC. The company was founded in 2005 and is headquartered in New York, New York.

MarketRank

Overall MarketRank

1.58 out of 5 stars

Analyst Opinion: 2.4Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Business services, not elsewhere classified
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone888-654-7473
Employees532

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$124.78 million
Book Value$2.84 per share

Profitability

Net Income$-20,290,000.00

Miscellaneous

Market Cap$2.83 billion
Next Earnings Date4/28/2021 (Estimated)
OptionableNot Optionable
$64.05
+1.09 (+1.73 %)
(As of 01/19/2021 12:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PHR News and Ratings via Email

Sign-up to receive the latest news and ratings for PHR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Phreesia (NYSE:PHR) Frequently Asked Questions

How has Phreesia's stock price been impacted by Coronavirus?

Phreesia's stock was trading at $23.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PHR stock has increased by 173.4% and is now trading at $64.24.
View which stocks have been most impacted by COVID-19
.

Is Phreesia a buy right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Phreesia in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Phreesia stock.
View analyst ratings for Phreesia
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Phreesia?

Wall Street analysts have given Phreesia a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Phreesia wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Phreesia's next earnings date?

Phreesia is scheduled to release its next quarterly earnings announcement on Wednesday, April 28th 2021.
View our earnings forecast for Phreesia
.

How were Phreesia's earnings last quarter?

Phreesia, Inc. (NYSE:PHR) announced its quarterly earnings data on Monday, December, 7th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.01. The business had revenue of $38.50 million for the quarter, compared to the consensus estimate of $35.56 million. Phreesia had a negative net margin of 16.37% and a negative return on equity of 16.07%. The company's revenue was up 17.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.07) earnings per share.
View Phreesia's earnings history
.

What guidance has Phreesia issued on next quarter's earnings?

Phreesia issued an update on its FY 2021 After-Hours earnings guidance on Tuesday, December, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $146-147 million, compared to the consensus revenue estimate of $140.9 million.

What price target have analysts set for PHR?

12 brokerages have issued 12 month price targets for Phreesia's shares. Their forecasts range from $30.00 to $70.00. On average, they anticipate Phreesia's stock price to reach $50.00 in the next year. This suggests that the stock has a possible downside of 22.2%.
View analysts' price targets for Phreesia
or view Wall Street analyst' top-rated stocks.

Who are some of Phreesia's key competitors?

What other stocks do shareholders of Phreesia own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Phreesia investors own include Fastly (FSLY), Zscaler (ZS), Okta (OKTA), DocuSign (DOCU), HealthEquity (HQY), Square (SQ), Appian (APPN), The Walt Disney (DIS), Globant (GLOB) and Invitae (NVTA).

Who are Phreesia's key executives?

Phreesia's management team includes the following people:
  • Mr. Chaim Indig, Co-Founder, CEO & Director (Age 41, Pay $422k)
  • Mr. Evan Roberts, Co-Founder & COO (Age 41, Pay $358.03k)
  • Mr. Thomas Altier, Chief Financial Officer (Age 70, Pay $360.95k)
  • Mr. Randy Rasmussen, Chief Accounting Officer
  • Mr. Daniel Nathan, Chief Technology Officer (Age 43)
  • Mr. Balaji Gandhi, VP of Investor Relations
  • Ms. Allison C. Hoffman, Gen. Counsel (Age 49)
  • Mr. Michael J. Davidoff, Sr. VP of Marketing & Bus. Devel. (Age 47)
  • Ms. Amy Beth VanDuyn, Sr. VP of HR (Age 47)
  • Mr. Will Rideout, Sr. VP of Provider Sales

When did Phreesia IPO?

(PHR) raised $127 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 7,800,000 shares at $15.00-$17.62 per share. J.P. Morgan, Wells Fargo Securities, William Blair, Allen & Company and Piper Jaffray acted as the underwriters for the IPO.

What is Phreesia's stock symbol?

Phreesia trades on the New York Stock Exchange (NYSE) under the ticker symbol "PHR."

Who are Phreesia's major shareholders?

Phreesia's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Legacy Advisors LLC (0.05%). Company insiders that own Phreesia stock include Amy Beth Vanduyn, Chaim Indig, Charles Kallenbach, Cheryl Pegus, Daniel Nathan, David Linetsky, Edward L Cahill, Evan Roberts, Gillian Munson, Ii LP Chv, Mark Douglas Smith, Michael J Davidoff, Michael Weintraub, Polaris Venture Management Co, Scott Perricelli and Thomas Altier.
View institutional ownership trends for Phreesia
.

Which institutional investors are selling Phreesia stock?

PHR stock was sold by a variety of institutional investors in the last quarter, including Legacy Advisors LLC. Company insiders that have sold Phreesia company stock in the last year include Amy Beth Vanduyn, Chaim Indig, Charles Kallenbach, Cheryl Pegus, Daniel Nathan, David Linetsky, Edward L Cahill, Evan Roberts, Gillian Munson, Mark Douglas Smith, Michael J Davidoff, Michael Weintraub, and Thomas Altier.
View insider buying and selling activity for Phreesia
or view top insider-selling stocks.

How do I buy shares of Phreesia?

Shares of PHR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Phreesia's stock price today?

One share of PHR stock can currently be purchased for approximately $64.24.

How big of a company is Phreesia?

Phreesia has a market capitalization of $2.84 billion and generates $124.78 million in revenue each year. The company earns $-20,290,000.00 in net income (profit) each year or ($4.50) on an earnings per share basis. Phreesia employs 532 workers across the globe.

What is Phreesia's official website?

The official website for Phreesia is www.phreesia.com.

How can I contact Phreesia?

Phreesia's mailing address is 432 Park Avenue South 12th Floor, New York NY, 10016. The company can be reached via phone at 888-654-7473 or via email at [email protected]

This page was last updated on 1/19/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.